Home » Stocks » Cytokinetics

Cytokinetics, Inc. (CYTK)

Stock Price: $22.66 USD 1.04 (4.81%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.35B
Revenue (ttm) 22.23M
Net Income (ttm) -131.73M
Shares Out 70.39M
EPS (ttm) -2.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $22.66
Previous Close $21.62
Change ($) 1.04
Change (%) 4.81%
Day's Open 21.63
Day's Range 21.45 - 22.83
Day's Volume 568,384
52-Week Range 7.73 - 29.20

More Stats

Market Cap 1.35B
Enterprise Value 1.26B
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 70.39M
Float 52.59M
EPS (basic) -2.23
EPS (diluted) -2.25
FCF / Share -1.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.18M
Short Ratio 10.79
Short % of Float 15.91%
Beta 1.43
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 60.62
PB Ratio n/a
Revenue 22.23M
Operating Income -104.71M
Net Income -131.73M
Free Cash Flow -97.54M
Net Cash 84.88M
Net Cash / Share 1.43
Gross Margin -266.58%
Operating Margin -471.06%
Profit Margin -592.60%
FCF Margin -438.79%
ROA -28.76%
ROE -729.94%
ROIC -46.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$40.25*
(77.63% upside)
Low
31.0
Current: $22.66
High
59.0
Target: 40.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue26.8731.5013.3710628.6646.9430.657.564.002.58
Revenue Growth-14.71%135.64%-87.44%271.3%-38.95%53.16%305.45%88.98%55.22%-
Gross Profit26.8731.5013.3710628.6646.9430.657.564.002.58
Operating Income-98.87-88.92-11318.69-37.41-14.75-33.89-40.46-47.96-49.64
Net Income-122-106-12816.45-37.50-14.65-33.72-40.37-47.86-49.29
Shares Outstanding57.5854.4249.4039.9438.8135.7127.2818.1111.8010.69
Earnings Per Share-2.11-1.95-2.590.39-0.97-0.41-1.24-2.30-4.30-4.62
Operating Cash Flow-90.91-101-10236.984.88-44.84-7.72-33.44-45.60-44.83
Capital Expenditures-2.62-0.88-2.88-1.56-0.56-1.10-0.53-0.12-0.44-0.48
Free Cash Flow-93.53-102-10535.424.32-45.95-8.25-33.56-46.04-45.31
Cash & Equivalents22519926915611183.2377.7374.0049.2272.43
Total Debt13442.4131.7829.8814.64---0.150.99
Net Cash / Debt91.2415623712696.8083.2377.7374.0049.0771.44
Assets29021129517011513383.1977.5552.7777.99
Liabilities30118518575.7846.6540.9028.757.474.607.48
Book Value-10.9425.9311094.3668.5992.0654.4470.0948.1870.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cytokinetics, Inc.
Country United States
Employees 156
CEO Robert I. Blum

Stock Information

Ticker Symbol CYTK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CYTK
IPO Date April 29, 2004

Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.